An emerging treatment option for glaucoma: Rho kinase inhibitors

Sean K Wang1
Robert T Chang2
1Stanford University, Stanford, CA, USA; 2Stanford University School of Medicine, Stanford, CA, USA

Abstract: Rho kinase (ROCK) inhibitors are a novel potential class of glaucoma therapeutics with multiple compounds currently in Phase II and III US Food and Drug Administration trials in the United States. These selective agents work by relaxing the trabecular meshwork through inhibition of the actin cytoskeleton contractile tone of smooth muscle. This results in increased aqueous outflow directly through the trabecular meshwork, achieving lower intraocular pressures in a range similar to prostaglandins. There are also animal studies indicating that ROCK inhibitors may improve blood flow to the optic nerve, increase ganglion cell survival, and reduce bleb scarring in glaucoma surgery. Given the multiple beneficial effects for glaucoma patients, ROCK inhibitors are certainly a highly anticipated emerging treatment option for glaucoma.

Keywords: ROCK inhibitors, actin cytoskeleton, aqueous dynamics review

Introduction
Glaucoma is an optic neuropathy in which at least one eye has accelerated ganglion cell death characterized by excavated cupping appearance of the optic nerve with progressive thinning of retinal nerve fiber layer tissue and corresponding subsequent visual field loss. As the leading cause of irreversible blindness worldwide, the disease affected more than 60.5 million individuals in 2010, an estimate extrapolated from multiple population-based surveys, and is projected to reach 79.6 million by the year 2020.1,2 Because of its initial asymptomatic nature, especially in the early stages, glaucoma may remain undiagnosed in up to half of total cases in developed nations and even more in regions of the developing world, where the incidence may be higher at older age and with certain ethnicities.3,4 Historically, intraocular pressure (IOP) has been recognized as the primary modifiable risk factor. It is now accepted as a continuous, fluctuating variable. The goal of contemporary therapy is to reduce IOP to a range that preserves structural and functional testing results.5–7 Present strategies to slow the rate of glaucomatous progression all focus on lowering IOP, as other strategies such as neuroprotection have not met their clinical trial endpoints. At this time, IOP can be lowered by affecting inflow and outflow via pharmacologic agents (five current classes include prostaglandin analogs, beta-blockers, carbonic anhydrase inhibitors, sympathomimetics, and miotics), laser trabeculoplasty, and incisional surgery, which can be divided into standard filtration surgery or various newer minimally invasive procedures.8–11 Current research is also looking beyond lowering IOP, with a focus on protecting or regenerating the optic nerve as well as novel targets to decrease inflow or increase outflow including small interfering RNA, cytoskeleton agents, cannabinoids, adenosine-serotonin/dopamine receptor ligands, nitric oxide/carbon monoxide system modulators, and hydroxysteroid dehydrogenase inhibitors.12
Aqueous dynamics review

To understand new pharmacologic targets for IOP reduction, it is best to review normal aqueous humor dynamics. IOP is a complex homeostatic process, but it can be simplified by comparing the rate of aqueous humor formation inside the posterior chamber against the rate of aqueous humor exiting the anterior chamber. Aqueous humor formation occurs in the ciliary epithelium lining the ciliary processes of the ciliary body and is created through a combination of passive diffusion and ultrafiltration, with the majority of aqueous derived from active secretion via selective transcellular movement of molecules mediated by protein transporters. Thus, enzymes and receptors found in the pigmented and nonpigmented ciliary epithelium are current drug targets to reduce aqueous humor production. How exactly the eye detects pressure to affect the rate of aqueous formation is not known, although circadian variation and maintenance of stable IOP indicates adjustable control over inflow and outflow until compromised in the disease state.

Once produced, aqueous makes its way from the posterior chamber to the anterior chamber and is traditionally believed to drain out of the eye through either the conventional pathway via the trabecular meshwork (TM) or the unconventional pathway via the uveoscleral route. However, the exact route is not known, as there is no reliable real-time observation method. The downstream conventional pathway drains into Schlemm’s canal, collector channels, and eventually the episcleral venous system. Outflow resistance has been classically associated with the juxtacanalicular portion of TM mediated through extracellular matrix, but resistance may also be mediated by the permeability of the endothelial cell lining of Schlemm’s canal. The uveoscleral unconventional pathway empties into spaces of the ciliary muscle and into the suprachoroidal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space. More recently, a novel “uveolymphatic” pathway in animal space. Existing pharmacologic agents target both outflow pathways, and newer surgical devices currently under development are capitalizing on the suprachoroidal drainage space.
Rho kinase inhibitors and glaucoma

regulate aspects of cell shape, motility, proliferation, and apoptosis throughout the body. On activation by binding to GTP, Rho activates its effector molecules (Rho kinase ROCK1 and 2), which signal downstream molecules to polymerize actin fibers in the cardiovascular, pulmonary, and renal systems. Rho GTPases were first hypothesized to function in aqueous humor outflow in 2001 because of their expression in TM, with the ability to induce calcium-sensitization in smooth muscle contraction in rabbit eyes. Since then, significantly elevated levels of RhoA have been detected by immunostaining in the optic nerve head of glaucomatous eyes compared with age-matched controls, reinforcing the association of Rho proteins and glaucoma pathophysiology.

ROCKs are serine/threonine kinases that regulate smooth muscle contraction in which selective ROCK inhibitors could increase aqueous humor drainage through the TM, leading to a decrease in IOP. In mammals, ROCKs exist as two isoforms: ROCK1, which is located on chromosome 18 and contains 1,354 amino acids, and ROCK2, which is located on chromosome 12 and encodes a 1,388-amino acid product. Overall, ROCK1 and ROCK2 share 65% homology in amino acid sequence with 92% homology in their kinase domains. In humans, ROCK1 and ROCK2 tend to be expressed in the majority of tissues, including human TM and ciliary muscle cells. Structurally, ROCKs are composed of three major domains: an N-terminal kinase domain that phosphorylates protein targets, a C-terminal autoinhibitory domain that limits kinase activity via intramolecular interactions, and a coiled-coil Rho-binding domain that appears to facilitate the switch from the inactive to active conformation. On binding to Rho, the catalytic activity of ROCKs is moderately enhanced, although activation of the kinase can also occur in response to lipids such as arachidonic acid. This may be important in linking cholesterol-lowering statin use and reduced risk for glaucoma.

Among other substrate targets, ROCKs inhibit myosin light chain phosphatase by phosphorylating the myosin-binding subunit, thereby mediating actin cytoskeletal changes and inducing vasoconstriction. Analogously, ROCKs activate LIM kinases via phosphorylation, which in turn stabilize filamentous actin and reduce the occurrence of cell migration. The exact molecular mechanism of depolymerization of filamentous actin leading to increased outflow has not been fully worked out, but it has been hypothesized that wider empty spaces in the juxtacanalicular region and increased vacuoles in endothelial cells improve outflow volume. Other targets of ROCKs include CPI-17 (a phosphoprotein phosphatase inhibitor), sodium/hydrogen exchange protein, adducin, and the ezrin/radixin/moesin family of actin-binding proteins. Thus, ROCKs appear to have several actin cytoskeletal-related targets that directly affect the contractile properties of TM outflow tissue (Figure 1). Loss of ROCK function has previously been associated with

Figure 1 Role and regulation of Rho kinase.
Abbreviations: ROCK, Rho kinase; MLC, myosin light chain; MLCP, myosin light chain phosphatase.
micromechanical relaxation of cells and disassembly of stress fibers and focal adhesion complexes. In contrast, overexpression of ROCK activity is observed in tumor metastasis, with loss of cytoskeletal regulation, and may promote tumor invasion. Therefore, ROCKs may play a role in further elucidating glaucoma pathogenesis as well as ROCK inhibitors becoming a new category in glaucoma therapeutics.

ROCK inhibitors and IOP

Multiple studies have indicated that ROCK and Rho GTPase inhibitors can increase aqueous humor drainage in TM tissue, leading to a reduction in IOP. As defined by current models, ROCK inhibitors induce reversible modifications to cell morphology and cell interactions in the eye that facilitate greater outflow of aqueous humor and, ultimately, result in a lower IOP. According to perfusion studies performed by Rao et al using enucleated porcine eyes, 10–100 µM ROCK inhibitor Y-27632 increased aqueous humor outflow through cells of the TM by up to 80% in a dose-dependent manner. Compared with control specimens, drug-treated samples exhibited a widening of the extracellular spaces and juxtacanalicular tissue, which resulted in an overall distended appearance. Moreover, on isolation of TM tissue from eyes perfused with the ROCK inhibitor, a decrease in myosin light chain phosphorylation was observed, suggesting that the changes in cell morphology and aqueous outflow were influenced by actomyosin cytoskeletal organization.

Previous experiments using a spectrum of ROCK inhibitors have correlated morphological changes in the TM and juxtacanalicular regions with rapid and long-lasting IOP reductions active within 30 minutes of administration and lasting up to 12 hours. In a seminal paper in 2001, Honjo et al measured the IOP and outflow facility of 18 rabbit eyes in vitro before and after topical, intracameral, or intravitreal administration of Y-27632. Within a 3-hour period, topical and intracameral delivery of Y-27632 decreased IOP by 30% and produced a two fold increase in trabecular outflow, thereby linking the observed IOP-lowering effects to altered TM cell behavior. In live rabbits, topical administration of two other ROCK inhibitors, H-1152P and HA-1077, both produced dose-dependent declines in IOP. For H-1152P, a maximum IOP-lowering effect of 7.2 mmHg (46.1%) versus control eyes was observed in normotensive animals at 28 mM dosing. Likewise, treatment of 18 ocular hypertensive rabbits with 3 mM HA-1077 lowered IOP by an average of 5.3 mmHg (46.4%). For both of these models, peak reductions were comparable with those of the antiglaucoma drug latanoprost, which decreased IOP by 22.6% and 40.3%, respectively, in normotensive and ocular hypertensive rabbit eyes.

In other animal models, ROCK inhibitors have similarly induced structural changes associated with decreased IOP levels. As demonstrated by Lu et al in 2008, perfusion of seven bovine eyes with Y-27632 resulted in a 58% enhancement, on average, in outflow activity and significant gains in effective filtration area compared with controls, as measured by fluorescent microspheres. In addition, after treatment with the inhibitor, regions of the juxtacanalicular connective tissue appeared to become more prevalent, supporting the notion that TM and juxtacanalicular cells were responsible for the increase in aqueous outflow facility. These findings have since been corroborated in mouse and monkey eyes by analogous studies observing IOP reductions with ROCK inhibitor Y-39983. Based on the consistent behavior of these compounds across multiple animal models as IOP-lowering agents, translational work began as companies started human trials.

Other applications of Rho kinase inhibitors in glaucoma

Reportedly, ROCK inhibitors may have uses in glaucoma management other than lowering IOP. Animal studies have demonstrated increased ocular blood flow as well as potential neuroprotective effects, and ROCK inhibitors may also have the potential to reduce postoperative scarring during glaucoma-filtering surgery. In a 2011 paper by Tokushige et al a 0.05% solution of Y-39983 was topically administered to the eyes of six live rabbits. For each of these animals, blood flow in the optic nerve head was significantly improved after treatment, presumably through the relaxation of vascular endothelial smooth muscle. Similarly, in 2011, Sugiyama et al showed that both intravenous and topical doses of Fasudil (Asahi Kasei Corporation, Tokyo, Japan), a ROCK inhibitor, prevented impairment of optic nerve blood flow by a known nitric oxide synthase inhibitor in rabbits, thereby reinforcing the ability of ROCK inhibitors to mediate normal blood flow in the eye. Considering the theorized role of disrupted ocular blood flow in glaucoma pathogenesis, and especially in patients with normal-tension glaucoma, these data hint at an additional therapeutic advantage conferred by ROCK inhibitors.

Several investigators have studied ROCK inhibitor use with glaucoma filtering surgery, where it may also act to prevent postoperative scarring, one of the most common causes of failed glaucoma filtering surgery. As described by Meyer-ter-Vehn et al in 2006, activity of Y-27632 in human tendon fibroblasts blocked the assembly and contraction of transforming growth factor β-induced stress fibers normally implicated in myofibroblast transdifferentiation. Because a crucial step in
the wound-healing process is the transformation of fibroblasts to myofibroblasts, this finding implies that ROCK inhibitors may reduce postoperative scarring after glaucoma filtration surgery.60 Such a model is further supported by in vivo experiments in rabbits, in which topical instillation of 10 mM Y-27632 inhibited fibroproliferation and collagen deposition after glaucoma filtration surgery, leading to prolonged survival of the postoperative bleb and better surgical outcome.61

Finally, ROCK inhibitors appear to influence neuron survival and axon regeneration, as demonstrated by the neuroprotective effects of inhibitors for both Rho and ROCK in animal cells.35 In 2004, rat studies performed by Kitaoka et al62 found that intravitreal injection of animals with $10^{-5}$ M Fasudil (Asahi Kasei Corporation) protected against glutamate-related excitotoxicity in the retina and better preserved cells of the ganglion cell layer on exposure to N-methyl-D-aspartate.63 Moreover, as reported by Tokushige et al66 rat retinal ganglion cells treated with 10 or 100 µM Y-39983 exhibited increased axon regeneration, first under culture conditions and, subsequently, in vivo compared with saline-treated animals.58 Sagawa et al in 2007,63 observed that immediately after crushing the optic nerve in adult cats, injection of 10 µM Y-39983, but not control saline, into the vitreous was capable of inducing the crushed axons to regenerate and pass over the site of damage.63 Thus, ROCK inhibitors may possess therapeutic potential for axonal regeneration of ganglion cells in the treatment of diseases with degenerating axons such as glaucoma.

Clinical trials of Rho kinase inhibitors

To date, only one ROCK inhibitor, Fasudil (HA-1077; Asahi Kasei Corporation), has been marketed for clinical use in cerebral vasospasm.64 Given the risks associated with developing effective kinase inhibitors for a chronic condition such as glaucoma, current clinical studies have focused on drug candidates that are not only potent but also highly selective over other protein kinases.65 As of February 2014, four ROCK inhibitor-based drugs were actively undergoing human clinical trials (Table 1).

Among the farthest along in the clinical trial process is K-115, developed by Kowa (Aichi, Japan). During Phase I trials, 50 healthy volunteers were treated with placebo or K-115 in concentrations of 0.05%, 0.1%, 0.2%, 0.4%, and 0.8% in a stepwise manner, either as a single instillation or repeated twice daily for 7 days.64 Mean IOP reduction of up to 4.3 mmHg for the highest concentration of treatment was observed 1–2 hours after instillation. Regarding adverse effects, more than half of participants treated with K-115 showed slight to mild conjunctival hyperemia, which spontaneously resolved for all cases within several hours.64 During Phase II trials, dose-response treatment of 210 patients with primary open-angle glaucoma or ocular hypertension resulted in a mean IOP reduction of 4.5 mmHg for 0.4% K-115 after 2 hours. Outcomes of the drug at this concentration were statistically significant at all times, leading Tanihara et al to recommend twice-daily administration of 0.4% K-115 as the optimal dose to control IOP.65

Another promising ROCK inhibitor designed for glaucoma therapy is AR-13324, developed by Aerie Pharmaceuticals Inc., (Research Triangle Park, NC, USA) and expected to commence Phase III clinical trials soon. Characterized as “dual action”, AR-13324 acts to lower IOP by enhancing fluid outflow through the trabecular pathway while simultaneously decreasing fluid inflow to the eye. In rabbits, once-daily treatment with 0.04% AR-13324 produced maximal mean IOP reductions of up to 7.1 mmHg (27%) at 4 hours after dosing. Likewise, in monkeys, the same concentration of AR-13324 reduced mean IOP after 3 days of treatment by 7.5 mmHg (37%), 7.2 mmHg (36%), and 7.5 mmHg (37%), respectively, at 4, 8, and 24 hours after dosing.66 In June 2013, AR-13324 successfully completed its Phase IIb

Table 1 Clinical trials of Rho kinase inhibitors in glaucoma

<table>
<thead>
<tr>
<th>Compound</th>
<th>Organization</th>
<th>Highest development phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMA0076</td>
<td>Amakem, Diepenbeek, Belgium</td>
<td>Phase II</td>
</tr>
<tr>
<td>AR-12286</td>
<td>Aerie Pharmaceuticals Inc., Research Triangle Park, NC, USA</td>
<td>Phase II</td>
</tr>
<tr>
<td>AR-13324</td>
<td>Aerie Pharmaceuticals Inc.</td>
<td>Phase III</td>
</tr>
<tr>
<td>AT5907</td>
<td>Altheos Inc., South San Francisco, CA, USA</td>
<td>Phase II</td>
</tr>
<tr>
<td>DE-104</td>
<td>Santen-Ube, Osaka City and Ube City, Japan</td>
<td>Phase II</td>
</tr>
<tr>
<td>INS-115644</td>
<td>Merck, Whitehouse Station, NJ, USA</td>
<td>Phase I</td>
</tr>
<tr>
<td>INS-117548</td>
<td>Merck</td>
<td>Phase I</td>
</tr>
<tr>
<td>K-115</td>
<td>Kowa, Aichi, Japan</td>
<td>Phase III</td>
</tr>
<tr>
<td>PG324</td>
<td>Aerie Pharmaceuticals Inc.</td>
<td>Phase II</td>
</tr>
<tr>
<td>Y-39983; RKI-983; SNJ-1656</td>
<td>Senju, Tokyo, Japan; and Novartis Pharmaceuticals, Basel, Switzerland</td>
<td>Phase II</td>
</tr>
</tbody>
</table>

Note: *Compound development discontinued.
trial, demonstrating that once-daily administration could significantly lower IOP by 5.7–6.2 mmHg in patients with elevated IOP.

Beyond “dual action”, Aerie Pharmaceuticals Inc., has also proposed a “triple-action” therapy combining AR-13324 with latanoprost, the most frequently prescribed glaucoma medicine. Named PG324, the drug is presently undergoing Phase II trials and aims to become the first glaucoma eye drop, dosed once daily, employing three distinct mechanisms to lower IOP. A 28-day Phase Iib clinical trial for PG324 including approximately 300 patients is expected to begin in the first quarter of 2014, with results anticipated by midyear.

Last, the lead compound of Amakem (Diepenbeek, Belgium), AMA0076, completed its Phase I trials in 2013. Applied as eye drops, AMA0076 is unique in that outside the aqueous humor, the drug is rapidly converted into an inactive form that can subsequently be eliminated from the body, potentially reducing off-target activity and adverse effects such as hyperemia. Although findings from AMA0076’s clinical trials have yet to be published in the literature, company reports indicate that the compound achieved a mean IOP reduction of 3.7 mmHg with little to no observation of conjunctival hyperemia.

It is important to recognize that although many promising trials for ROCK inhibitor compounds are presently underway, a substantial number of candidates have already failed. Despite early success in animal studies and Phase I clinical trials,66,69 development of Y-39983, synonymous with RKI-983 and SNJ-1656, was terminated by Senju (Tokyo, Japan) and Novartis Pharmaceuticals (Basel, Switzerland) during Phase II trials. Similarly, progress on Aerie Pharmaceuticals Inc., AR-12286 was abandoned in June 2013 because of an inability to maintain significant IOP reduction over time. From Merck (Whitehouse Station, NJ, USA), both INS117548 and INS-115644 were discontinued during the Phase I stage, most likely because of safety and tolerability concerns in human patients. In late 2010, Santen-Ube, Osaka City and Ube City, Japan, also abandoned its ROCK inhibitor, DE-104, after a Phase II trial fell short of meeting the primary endpoint.71 Finally, ATS907, a topically administered drug designed by Altheos Inc., South San Francisco, CA, USA, exhibited initially favorable outcomes because of its wide therapeutic index and rapid conversion in the eye into a more potent and selective metabolite.72 However, after failed Phase II testing in 2012, the company ultimately closed down, underscoring the fact that not all ROCK inhibitors have demonstrated clinical efficacy in treating glaucoma without adverse effects.

**Therapeutic risks of Rho kinase inhibitors**

Of the four ROCK inhibitor-based drugs continuing clinical trials, all seem to have an optimistic safety profile, as indicated by Phase I results. The most common noted adverse effect is conjunctival hyperemia resulting from vasodilation of conjunctival vessels.70 No conjunctival hemorrhage was seen, but it has been noted in animal studies. Still, given the list of failed candidates discussed in this review, ROCK inhibitors are not without risk. Because ROCKs belong to a class of serine/threonine kinases, higher concentrations of these inhibitors may affect other protein kinases in the body, including protein kinase A, protein kinase C, and myosin light chain kinase, among others.42,50 Therefore, dosing of ROCK inhibitors must be carefully designed to minimize unintended cross-reactivity with alternate kinase pathways.

On a systemic level, ROCK inhibition is known to lower blood pressure and vascular resistance, thus bearing potential consequences in case of unwanted systemic exposure.35 To avoid these risks in the context of glaucoma, drugs such as AMA0076 have been developed with the objective of remaining active only within the aqueous humor. From ongoing clinical trials, it is also evident that the major adverse effect of most, if not all, ROCK inhibitors is ocular hyperemia, most likely because of the pharmacology of these agents as vasodilators.66,69 Considering the spontaneous resolution of adverse hyperemia typically within several hours, one option in future practice may be to have the drug administered at bedtime to mitigate any negative appearance. Notably, Arnold et al in 2013,73 observed that on concurrent administration, ROCK inhibition reduced the intraocular penetration of beta-blocker timolol maleate, presumably because of increased systemic elimination through the conjunctival vasculature.73 In view of the much-anticipated release of a ROCK inhibitor for glaucoma treatment, clinicians should be wary of this and similar confounding interactions, particularly in the prescribing of new drug regimens to address the disease.

**Conclusion**

As a novel class of pharmacological agents to slow down glaucomatous progression, ROCK inhibitors have been reported to offer at least four distinct applications relevant to glaucoma management, including significant IOP-lowering effects, improvement in ocular blood flow, inhibition of postoperative scarring, and promotion of retinal ganglion cell survival and axon regeneration. In contrast to the wide variety of glaucoma drugs today, which, in general, reduce IOP by suppressing aqueous humor production, ROCK inhibitors

---

**Clinical Ophthalmology** 2014:8
appear to facilitate greater aqueous outflow by mediating actomyosin regulation, thereby ultimately lowering IOP. Over the past decade, a considerable number of ROCK inhibitor candidates have failed during clinical testing, most often because of insufficient efficacy or unforeseen adverse effects such as hyperemia. Nonetheless, four ROCK inhibitor-based drugs (K-115, AR-13324, PG324, AM0A076) have continued to show promise as future glaucoma therapeutics. Ongoing clinical trials for each of these compounds are crucial to the development of better IOP-lowering therapies and may initiate the next major advancement in the treatment of glaucoma.

Disclosure
The authors report no conflicts of interest in this work.

References


